QA: Bellerophon Therapeutics Inc in us_pharma/2016

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001600132_2017_Bellerophon_Therapeutics_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning Missing logo subcommand.report {}
info NetIncome node detected by tax heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'NetIncomeLossAvailableToCommonStockholdersBasic'}

Graph

Absolute values for 0001600132, Bellerophon Therapeutics Inc

  xvar xval
0 AssetsCurrent 26,505,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 1,399,000
3 remainder_Assets 1,798,000
4 LiabilitiesCurrent 6,495,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 5,215,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 7,107,000
9 ResearchAndDevelopmentExpense 16,650,000
10 remainder_Expenses 152,000
11 remainder_Revenues 0
12 remainder_NetIncome 95,000
13 remainder_ComprehensiveNetIncome 19,000
  yvar yval
0 Assets 29,702,000
1 Liabilities 11,710,000
2 Expenses 23,909,000
3 Revenues 0
4 StockholdersEquity 17,992,000
5 NetIncome -23,814,000
6 ComprehensiveNetIncome -23,804,500
7 BaseVar 32,717,500
8 EconomicCapitalRatiobeforeLimitedLiability 0.745
9 EconomicCapitalRatio 2.09

Edgar->Model Mapping

Feature Distribution

Change over Time